So far, multiple studies have demonstrated the ability of metformin to activate the hepatic insulin receptor and the IRS2/PI3K/Akt pathway resulting in reduced insulin resistance and increased glucose uptake [50, 51]. The gene discussed is IRS2; the disease is Insulin resistance.